Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese

Chengzhi Wang, Lingling Guo, Baiyu Han, Anping Wang, Hongyan Liu, Xing Su, Qinghua Guo, Yiming MuInternational Journal of Endocrinology 2016 · DOI

TL;DR

This study retrospectively analyzed 75 Han Chinese patients with Pituitary Stalk Interruption Syndrome (PSIS) and short stature, finding that growth hormone (GH) therapy significantly improved final height and height gain, even when initiated in adolescence or adulthood. The findings suggest that at least 12 months of GH therapy is most beneficial, offering hope for patients in developing countries where diagnosis and treatment are often delayed.

What Problem Does This Paper Address?

Pituitary Stalk Interruption Syndrome (PSIS) is a rare congenital condition leading to anterior pituitary hormone deficiencies, often presenting as short stature. While GH therapy is a known treatment for growth hormone deficiency (GHD), its long-term benefits for PSIS patients, particularly adolescents and adults, have been less clear. Previous studies primarily focused on early childhood treatment and catch-up growth. This paper aims to fill this gap by evaluating the efficacy of GH therapy on final height and total height gain in a cohort of PSIS patients, including those diagnosed and treated later in life, which is common in developing countries due to diagnostic challenges and treatment costs.

Methods

This was a retrospective study involving 75 Han Chinese patients diagnosed with PSIS and short stature. Data on initial and final height, height gain, and GH treatment history were collected via telephone calls and medical records. Patients were categorized into GH-treated (n=51) and untreated (n=24) cohorts. Height was measured using Standard Deviation Scores (SDS) relative to chronological age (CA) and bone age (BA). GH therapy involved subcutaneous injections of recombinant human growth hormone for six days a week. Statistical analyses, including Mann-Whitney U tests, Kruskal-Wallis tests, t-tests, and Wilcoxon tests, were used to compare groups and assess correlations.

Datasets

The study utilized retrospective clinical data from 75 PSIS patients treated at the Chinese PLA General Hospital between 2004 and 2014. This dataset includes patient demographics, medical histories, hormonal evaluations, auxological measurements (height, bone age), and GH treatment details. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • GH Therapy is Effective Even in Later Stages: Contrary to the emphasis on early intervention, this study demonstrates that GH therapy can still yield significant height gains and improve final height in PSIS patients who are adolescents or adults at the time of treatment.
  • Duration Matters: The findings strongly suggest that longer durations of GH therapy are associated with greater height gains. Specifically, treatment for at least 12 months (GH 3 group) showed significantly better outcomes compared to shorter durations or no treatment.
  • Delayed Diagnosis is Common and Treatable: The study highlights that PSIS patients, particularly in developing countries like China, often face delayed diagnoses and treatment initiation due to various factors. However, GH therapy remains a viable and effective option even in these scenarios.
  • Bone Age as a Predictor: Bone age and delayed bone age showed a slight positive correlation with initial BA and final height, and delayed BA correlated with height gain, suggesting these could be useful indicators for treatment evaluation.
  • Hormone Replacement Synergy: Patients receiving sex hormone or gonadotropin replacement therapy alongside GH therapy showed better final heights, indicating a potential synergistic effect.

Key Results

  • Overall Height Gain: GH-treated patients experienced a significantly greater height gain (SDS) compared to untreated patients (0.55 vs. 0.34, P = 0.011).
  • Final Height Improvement: The final height SDS for GH-treated patients improved from -1.99 ± 1.91 to -1.47 ± 1.64 (P = 0.016).
  • Treatment Duration Impact: Significant differences in height gain were observed between treatment duration groups, with the group receiving GH for over 12 months (GH 3) showing the most substantial gains compared to untreated (GH 0), 1-6 months (GH 1), and 6-12 months (GH 2) groups (P = 0.001).
  • Catch-up Growth: While not all patients reached normal height, a notable proportion of GH-treated patients (21/51) were no longer considered short after treatment.
  • Correlation: Delayed bone age was correlated with height gain (r = 0.263, P = 0.028).

Limitations and Future Work

  • Retrospective Design: The study's retrospective nature means data collection was dependent on existing records, potentially leading to recall bias or missing information.
  • Sample Size: While 75 patients is a reasonable number, the authors suggest a larger sample size would be beneficial for more explicit results and to better balance the data, especially for the untreated cohort.
  • Growth Rate Data: Growth rates were not routinely recorded annually for all participants, limiting detailed analysis of growth velocity.
  • IGF-1 Data: Insufficient IGF-1 data (before and during GH therapy) was collected, which the authors suggest should be routinely measured in future studies to aid in GH dose adjustment and treatment completion decisions.
  • Future Directions: The authors advocate for continued research into the long-term effects of GH therapy, the role of other hormone replacements, and the importance of measuring IGF-1 for optimizing treatment strategies. They also emphasize the need for increased attention to rural healthcare and early screening for rare diseases like PSIS in developing countries.

Summary updated

Abstract

Objective. We aim to investigate the long-term benefits of growth hormone (GH) therapy in short stature adolescents and adults with pituitary stalk interruption syndrome (PSIS), which would be beneficial for future clinical applications. Design and Methods. In this study, initial height, final height, total height gain, and GH treatment history were retrospectively investigated in 75 Chinese PSIS patients. We compared height gain between the GH treated cohort and untreated cohort and explored the impact of different GH therapy duration on height gain. Results. For GH treated patients, their final height (SDS) increased from -1.99 ± 1.91 (-6.93~2.80) at bone age (BA) of 11.2 (5.0~17.0) years to -1.47 ± 1.64 (-7.82~1.05) at BA of 16.6 (8.0~18.0) years (P = 0.016). And GH treated patients had more height gain than the untreated patients (P < 0.05). There was a significant difference between the different GH therapy duration groups (P = 0.001): GH 0 versus GH 3, P = 0.000; GH 1 versus GH 3, P = 0.028; GH 2 versus GH 3, P = 0.044. Conclusion. Adult Chinese PSIS patients with short stature benefited the most from at least 12 months of GH therapy. Although patient diagnosis age was lagged behind in the developing countries, GH treatment was still effective for them and resulted in a higher final height and more height gain.
BibTeX
@article{wang2016growth,
  author = {Chengzhi Wang and Lingling Guo and Baiyu Han and Anping Wang and Hongyan Liu and Xing Su and Qinghua Guo and Yiming Mu},
  title = {{Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese}},
  journal = {International Journal of Endocrinology},
  year = {2016},
  doi = {10.1155/2016/1896285},
}
Figure